Pacific Edge has confirmed no capital raising has been approved by its board after details of a share offer were mistakenly released on the ASX, where it is seeking to list.
The NZX-listed cancer diagnostics firm said it was aware of market speculation in relation to a potential capital raise, due to incorrect information inadvertently released by the ASX to the market, which had been withdrawn by the exchange.
"The company continually monitors its capital management needs and no capital raising has been approved by the board," it said in a statement.
"Pacific Edge advises that the process for approval to dual list as a Foreign Exempt Entity on the Australian Stock Exchange (ASX) is progressing well," it said.